

Fusanori Yotsumoto

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2113002/publications.pdf>

Version: 2024-02-01

34
papers

641
citations

759233

12
h-index

580821

25
g-index

35
all docs

35
docs citations

35
times ranked

1058
citing authors

#	ARTICLE	IF	CITATIONS
1	Validation of HB-EGF and amphiregulin as targets for human cancer therapy. <i>Biochemical and Biophysical Research Communications</i> , 2008, 365, 555-561.	2.1	113
2	Separation efficiency of a microfluidic sperm sorter to minimize sperm DNA damage. <i>Fertility and Sterility</i> , 2016, 105, 315-321.e1.	1.0	90
3	Microbiome profile of the amniotic fluid as a predictive biomarker of perinatal outcome. <i>Scientific Reports</i> , 2017, 7, 12171.	3.3	86
4	Amphiregulin regulates the activation of ERK and Akt through epidermal growth factor receptor and HER3 signals involved in the progression of pancreatic cancer. <i>Cancer Science</i> , 2010, 101, 2351-2360.	3.9	46
5	Molecular Hierarchy of Heparin-Binding EGF-like Growth Factor Regulated Angiogenesis in Triple-Negative Breast Cancer. <i>Molecular Cancer Research</i> , 2013, 11, 506-517.	3.4	45
6	NG2 Proteoglycan-Dependent Contributions of Pericytes and Macrophages to Brain Tumor Vascularization and Progression. <i>Microcirculation</i> , 2016, 23, 122-133.	1.8	38
7	HB-EGF orchestrates the complex signals involved in triple-negative and trastuzumab-resistant breast cancer. <i>International Journal of Cancer</i> , 2010, 127, 2707-2717.	5.1	37
8	NG2 proteoglycan-dependent recruitment of tumor macrophages promotes pericyte-endothelial cell interactions required for brain tumor vascularization. <i>Oncotmmunology</i> , 2015, 4, e1001204.	4.6	35
9	MicroRNA-135a-3p as a promising biomarker and nucleic acid therapeutic agent for ovarian cancer. <i>Cancer Science</i> , 2017, 108, 886-896.	3.9	32
10	HB-EGF Is A Promising Therapeutic Target for Lung Cancer with Secondary Mutation of EGFR790M. <i>Anticancer Research</i> , 2017, 37, 3825-3831.	1.1	16
11	Efficacy of ligand-based targeting for the EGF system in cancer. <i>Anticancer Research</i> , 2009, 29, 4879-85.	1.1	16
12	Serum Heparin-binding Epidermal Growth Factor-like Growth Factor (HB-EGF) as a Biomarker for Primary Ovarian Cancer. <i>Anticancer Research</i> , 2017, 37, 3955-3960.	1.1	12
13	The combination of maternal blood and amniotic fluid biomarkers improves the predictive accuracy of histologic chorioamnionitis. <i>Placenta</i> , 2019, 80, 4-7.	1.5	10
14	Adipose tissue-derived regenerative cells improve implantation of fertilized eggs in thin endometrium. <i>Regenerative Medicine</i> , 2020, 15, 1891-1904.	1.7	10
15	Anti-tumor Effect of Intravenous Administration of CRM197 for Triple-negative Breast Cancer Therapy. <i>Anticancer Research</i> , 2016, 36, 3651-7.	1.1	9
16	BK-UM in patients with recurrent ovarian cancer or peritoneal cancer: a first-in-human phase-I study. <i>BMC Cancer</i> , 2017, 17, 89.	2.6	8
17	Vaginal microbiome as a tool for prediction of chorioamnionitis in preterm labor: a pilot study. <i>Scientific Reports</i> , 2021, 11, 18971.	3.3	8
18	Pre-clinical study of BK-UM, a novel inhibitor of HB-EGF, for ovarian cancer therapy. <i>Anticancer Research</i> , 2014, 34, 4615-20.	1.1	8

#	ARTICLE	IF	CITATIONS
19	Association of Serum HB-EGF Value and Response to Chemotherapy in Patients with Recurrent Ovarian Cancer. <i>Anticancer Research</i> , 2018, 38, 4347-4351.	1.1	5
20	Clinical Features of Recurrence in Patients Without Residual Tumour in Endometrial Cancer. <i>Anticancer Research</i> , 2019, 39, 4581-4588.	1.1	5
21	Age-related changes in thickness of anterior lower uterine segment in normal singleton pregnancy during 20–35 weeks gestation. <i>Journal of Medical Ultrasonics</i> (2001), 2016, 43, 401-405.	1.3	3
22	Trophic and immunomodulatory effects of adipose tissue derived stem cells in a preclinical murine model of endometriosis. <i>Scientific Reports</i> , 2022, 12, 8031.	3.3	3
23	MicroRNAs miR-4535 and miR-1915-5p in amniotic fluid as predictive biomarkers for chorioamnionitis. <i>Future Science OA</i> , 2021, 7, FSO686.	1.9	2
24	Antitumour Effects of Intravenous Administration of BK-UM, a Novel Inhibitor of HB-EGF, in Ovarian Cancer Therapy. <i>Anticancer Research</i> , 2017, 37, 3891-3896.	1.1	2
25	Validity of HB-EGF as Target for Human Neuroblastoma Therapy. <i>Anticancer Research</i> , 2015, 35, 4433-40.	1.1	2
26	Change in cervical length in cases resulting in threatened preterm labor. <i>Journal of Medical Ultrasonics</i> (2001), 2010, 37, 195-200.	1.3	0
27	A case of secondary amenorrhea caused by uterine myoma successfully treated by a combined laparoscopic and hysteroscopic approach. <i>Gynecology and Minimally Invasive Therapy</i> , 2017, 6, 49-50.	0.9	0
28	A partial supernumerary umbilical vein: a case report. <i>Journal of Medical Case Reports</i> , 2019, 13, 149.	0.8	0
29	Peri-operative complications of Total laparoscopic hysterectomy for benign gynecological diseases in Fukuoka university. <i>Japanese Journal of Gynecologic and Obstetric Endoscopy</i> , 2021, 37, 7-13.	0.0	0
30	A Promising Therapeutic Implication of a Novel Bcl-2 Family Inhibitor ABT-737 for Adult T-Cell Leukemia/Lymphoma. <i>Blood</i> , 2008, 112, 1584-1584.	1.4	0
31	Targeting Bcl-2 Family Proteins in Adult T-Cell Leukemia/Lymphoma: In Vitro and In Vivo Effects of a Novel Bcl-2 Family Inhibitor ABT-737. <i>Blood</i> , 2009, 114, 1685-1685.	1.4	0
32	Perinatal outcomes after laparoscopic or abdominal myomectomy. <i>Japanese Journal of Gynecologic and Obstetric Endoscopy</i> , 2019, 35, 175-179.	0.0	0
33	Safety and Anti-tumor Effects of Docetaxel Plus Cisplatin in Intermediate- and High-risk Endometrial Cancer. <i>Anticancer Research</i> , 2016, 36, 3725-9.	1.1	0
34	Usefulness of LigaSure™ in laparoscopic salpingectomy for tubal pregnancy. <i>Japanese Journal of Gynecologic and Obstetric Endoscopy</i> , 2022, 38, 8-13.	0.0	0